The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.
The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.
Stocktwits on MSN
SRPT stock clocks highest daily gain in nearly 8 years after rare muscle disorders study data but Wall Street's not wholly convinced
Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." ・The firm now awaits ...
Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2 ...
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...
Muscle ultrasound has emerged as a pivotal, non‐invasive imaging modality that offers real‐time insights into muscle structure and pathology. This technique enables both qualitative and quantitative ...
A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results